multistage and single-stage incubation. The Prestage Department of Poultry Science Research and Teaching Units in Raleigh, NC conduct research at the Piedmont Research Station. Research at both unit locations includes commercial layers, commercial broiler breeders, broilers, and commercial-style incubation. Piedmont Research Station routinely conducts the Layer Performance Management Test in North America, with studies in applied production practices and nutrition management. These facilities are able to evaluate the effects of a research project on a size and scale that mimics commercial poultry operations.

The North Carolina State University feed mill is a research and educational feed mill that is designed and equipped to manufacture a variety of feed mix characteristics, formulations, and feed forms. It is currently used by FDA for training purposes associated with the safe feed-safe food program, and is among the few research feed mills in the country that is associated with animal research facilities. The mill has all of the typical process equipment found in commercial feed mills, including an 8 ton/hr CPM hammer mill, 8 ton/hr RMS roller mill, micro bin-batching system, a 500 lb horizontal ribbon mixer, a 2 ton double-shaft ribbon mixer, a 1 ton/hr CPM pellet mill with counter-flow cooler, a 10 ton/hr Bliss pellet mill with counter-flow cooler, pellet screener, bagger, bulk ingredient bins, finished feed bins, and an automated computer-controlled batch mixing and process operation. This feed mill is able to manufacture feed of various feed ingredient grind size in mash or pellet forms.

While other academic institutions also have outstanding poultry and egg research programs, they do not have commercial style research facilities, feed mill, and resources to conduct large-scale commercial size research projects. Moreover, the North Carolina State University, Prestage Department of Poultry Science and Piedmont Research Facility are within close geographic proximity for collaboration with FDA's Department of Immunobiology. This will allow FDA's investigational scientists to travel by automobile on key experimental dates to initiate research experiments and to collect tissue and environmental samples. These samples will be transported within 24 hours back to FDA's Department of Immunobiology for microbiological testing and analysis.

II. Award Information/Funds Available

A. Award Amount

The Center for Food Safety and Applied Nutrition (CFSAN) intends to fund one award up to $50,000 total costs (direct plus indirect costs) for FY 2013. Future year amounts will depend on annual appropriations and successful performance.

B. Length of Support

The award will provide 1 year of support and include future recommended support for 4 additional years, contingent upon satisfactory performance in the achievement of project and program reporting objectives during the preceding year and the availability of Federal fiscal year appropriations.

III. Electronic Application, Registration, and Submission

Only electronic applications will be accepted. To submit an electronic application in response to this FOA, applicants should first review the full announcement located at *www.fda.gov/food/newsevents/default.htm*. (FDA has verified the Web site addresses throughout this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the **Federal Register**.) For all electronically submitted applications, the following steps are required.

- Step 1: Obtain a Dun and Bradstreet (DUNS) Number
- Step 2: Register With System for Award Management (SAM)
- Step 3: Obtain Username & Password
- Step 4: Authorized Organization Representative (AOR) Authorization
- Step 5: Track AOR Status
- Step 6: Register With Electronic Research Administration (eRA) Commons

Steps 1 through 5, in detail, can be found at *http://www07.grants.gov/applicants/organization_registration.jsp*. Step 6, in detail, can be found at *https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp*. After you have followed these steps, submit electronic applications to: *http://www.grants.gov*.

Dated: June 17, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2013–14824 Filed 6–20–13; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–0001]

Request for Nominations for Voting and/or Nonvoting Consumer Representatives on Public Advisory Committees or Panels and Request for Notification From Consumer Organizations Interested in Participating in the Selection Process for Nominations for Voting and/or Nonvoting Consumer Representatives on Public Advisory Committees or Panels

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may either be self-nominated or may be nominated by a consumer organization. Nominations will be accepted for current vacancies and for those that will or may occur through December 2013.

DATES: Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see **ADDRESSES**) by July 22, 2013, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see **ADDRESSES**) by July 22, 2013.

ADDRESSES: All statements of interest from consumer organizations interested in participating in the selection process and consumer representative nominations should be sent electronically to *CV@OC.FDA.GOV,* by mail to Advisory Committee Oversight and Management Staff, 10903 New Hampshire Ave., WO32 Rm. 5129, Silver Spring Maryland 20993–0002, or by fax to 301–847–8640. Information about becoming a member of an FDA advisory committee can be obtained by

visiting FDA's Web site at *http://www.fda.gov/AdvisoryCommittees/default.htm.*

FOR FURTHER INFORMATION CONTACT: Dornette Spell-LeSane, Advisory Committee Oversight and Management Staff, Food and Drug Administration, White Oak Bldg. 32, 10903 New Hampshire Ave., Rm. 5129, Silver Spring, MD 20993–0002, 301–796–8224, email: *dornette.spelllesane@fda.hhs.gov.*

For questions relating to specific advisory committees or panels, contact the following persons listed in table 1:

TABLE 1—COMMITTEE CONTACT

Contact person	Committee/panel
Stephanie Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, White Oak Bldg 31, 10903 New Hampshire Ave., rm. 2408, Silver Spring, MD 20993–0002, 301–796–3693, FAX: 301–847–8533, email: *Stephanie.Bregansky@fda.hhs.gov*.	Anesthetic and Analgesic Drugs.
Diane Goyette, Center for Drug Evaluation and Research, Food and Drug Administration, White Oak Bldg 31, 10903 New Hampshire Ave., rm. 2408, Silver Spring, MD 20993–0002, 301–796–9014, FAX: 301–847–8533, email: *Diane.Goyette@fda.hhs.gov*.	Anti-Infective Drugs.
Nicole Vesely, Center for Drug Evaluation and Research, Food and Drug Administration, White Oak Bldg 31, 10903 New Hampshire Ave., rm. 2408, Silver Spring, MD 20993–0002, 301–796–0063, FAX: 301–847–8533, email: *Nicole.Vesely@fda.hhs.gov*.	Cardiovascular & Renal Drugs.
Cindy Hong, Center for Drug Evaluation and Research, Food and Drug Administration, White Oak Bldg 31, 10903 New Hampshire Ave., rm. 2528, Silver Spring, MD 20993–0002, 301–796–0889, FAX: 301–847–8533, email: *Cindy.Hong@fda.hhs.gov*.	Pulmonary Allergy Drugs.
Jamie Waterhouse, Center for Devices and Radiological Devices, Food and Drug Administration, White Oak Bldg 66, 10903 New Hampshire Ave., rm. 1611, Silver Spring, MD 20993–0002, 301–796–3063, FAX: 301–847–8116, email: *Jamie.Waterhouse@fda.hhs.gov*.	Circulatory System Devices.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting and/or nonvoting consumer representatives for the vacancies listed in table 2:

TABLE 2—COMMITTEE DESCRIPTION, TYPE OF CONSUMER REPRESENTATIVE VACANCY, AND APPROXIMATE TIME NEEDED

Committee/panel/areas of expertise needed	Current and upcoming vacancies	Approximate date needed
Anesthetic and Analgesic Drugs—Knowledgeable in the fields of anesthesiology, analgesics (such as abuse deterrent opioids, novel analgesics, and issues related to opioid abuse) epidemiology or statistics, and related specialties.	1—Voting	Immediately.
Anti-Infective Drugs—Knowledgeable in the fields of infectious disease, internal medicine, microbiology, pediatrics, epidemiology or statistics, and related specialties.	1—Voting	December 1, 2013.
Cardiovascular and Renal Drugs—Knowledgeable in the fields of cardiology, hypertension, arrhythmia, angina, congestive heart failure, diuresis, and biostatistics.	1—Voting	July 1, 2013.
Pulmonary Allergy Drugs—Knowledgeable in the fields of pulmonary medicine, allergy, clinical immunology, and epidemiology or statistics.	1—Voting	June 1, 2013.
Circulatory System Devices—Knowledgeable in the safety and effectiveness of marked and investigational devices for use in the circulatory and vascular systems.	1 Non-Voting	July 1, 2013.

I. Functions

A. Anesthetic and Analgesic Drug Products

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in anesthesiology and surgery and makes appropriate recommendations to the Commissioner of Food and Drugs.

B. Anti-Infective Drugs

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the Commissioner of Food and Drugs.

C. Cardiovascular and Renal Drugs

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cardiovascular and renal disorders and makes appropriate recommendations to the Commissioner of Food and Drugs.

D. Pulmonary-Allergy Drugs

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms and makes appropriate recommendations to the Commissioner of Food and Drugs.

E. Certain Panels of the Medical Devices Advisory Committee

The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. With the exception of the Medical Devices Dispute Resolution Panel, each panel, according to its specialty area: Advises on the classification or reclassification of devices into one of three regulatory categories; advises on any possible risks to health associated with the use of devices; advises on formulation of product development protocols; reviews premarket approval applications for medical devices; reviews guidelines and guidance documents; recommends exemption of certain devices from the application of portions of the Federal Food, Drug, and Cosmetic Act; advises

on the necessity to ban a device; and responds to requests from the Agency to review and make recommendations on specific issues or problems concerning the safety and effectiveness of devices. With the exception of the Medical Devices Dispute Resolution Panel, each panel, according to its specialty area, may also make appropriate recommendations to the Commissioner of Food and Drugs on issues relating to the design of clinical studies regarding the safety and effectiveness of marketed and investigational devices.

II. Criteria for Members

Persons nominated for membership as consumer representatives on the committees or panels should meet the following criteria: (1) Demonstrate ties to consumer and community-based organizations, (2) be able to analyze technical data, (3) understand research design, (4) discuss benefits and risks, and (5) evaluate the safety and efficacy of products under review. The consumer representative should be able to represent the consumer perspective on issues and actions before the advisory committee; serve as a liaison between the committee and interested consumers, associations, coalitions, and consumer organizations; and facilitate dialogue with the advisory committee on scientific issues that affect consumers.

III. Selection Procedures

Selection of members representing consumer interests is conducted through procedures that include the use of organizations representing the public interest and public advocacy groups. These organizations recommend nominees for the Agency's selection. Representatives from the consumer health branches of Federal, State, and local governments also may participate in the selection process. Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests should send a letter stating that interest to FDA (see **ADDRESSES**) within 30 days of publication of this document.

Within the subsequent 30 days, FDA will compile a list of consumer organizations that will participate in the selection process and will forward to each such organization a ballot listing at least two qualified nominees selected by the Agency based on the nominations received, together with each nominee's current curriculum vitae or resume. Ballots are to be filled out and returned to FDA within 30 days. The nominee receiving the highest number of votes ordinarily will be selected to serve as the member representing consumer interests for that particular advisory committee or panel.

IV. Nomination Procedures

Any interested person or organization may nominate one or more qualified persons to represent consumer interests on the Agency's advisory committees or panels. Self-nominations are also accepted. Potential candidates will be required to provide detailed information concerning such matters as financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

All nominations should include: A cover letter; a curriculum vitae or resume that includes the nominee's office address, telephone number, and email address; and a list of consumer or community-based organizations for which the candidate can demonstrate active participation.

Nominations also should specify the advisory committee(s) or panel(s) for which the nominee is recommended. In addition, nominations should include confirmation that the nominee is aware of the nomination and is willing to serve as a member of the advisory committee or panel if selected.

The term of office is up to 4 years. FDA will review all nominations received within the specified timeframes and prepare a ballot containing the names of qualified nominees. Names not selected will remain on a list of eligible nominees and be reviewed periodically by FDA to determine continued interest. Upon selecting qualified nominees for the ballot, FDA will provide those consumer organizations that are participating in the selection process with the opportunity to vote on the listed nominees. Only organizations vote in the selection process. Persons who nominate themselves to serve as voting or nonvoting consumer representatives will not participate in the selection process.

FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and therefore, encourages nominations of appropriately qualified candidates from these groups.

Dated: June 17, 2013.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2013–14889 Filed 6–20–13; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Maternal Health Town Hall Listening Session; Notice of Meeting

Name: Maternal Health Town Hall Listening Session.

Date and Time: August 27, 2013, 2:00 p.m.–3:30 p.m. (EST).

Place: Virtual via Webinar.

Status: The meeting is open to the public. The meeting will be hosted virtually through webinar and by phone. Participants will have an opportunity to interact with presenters via the chat function in the public comment section of the webinar system. In addition, there will be up to 100 phone lines available to individuals who choose to participate by phone. The phone lines will be made available on a first-come, first-served basis. To register for this meeting please go to: *http://learning.mchb.hrsa.gov/LiveWebcastDetail.asp?leid=333*. Registrations will be accepted through 5:00 p.m. EST on August 19, 2013. Call information for this meeting will be provided upon registration.

Purpose: The purpose of the meeting is to share and discuss proposed strategies and to solicit ideas in support of the National Maternal Health Initiative. The Town Hall Listening Session will serve as a platform to engage and obtain feedback from the public on HRSA's strategic thinking around a national strategy to reduce maternal morbidity and mortality, and improve the quality and safety of maternity care in the United States.

The desired outcomes of the meeting are:

I. To share with the public the Health Resources and Services Administration, Maternal and Child Health Bureau's (HRSA/MCHB): (1) Vision for promoting maternal health in the United States; (2) strategic direction for the National Maternal Health Initiative including mission, goals and objectives; and (3) identified priority areas to focus efforts to improve maternal health;

II. Enhance, guide, and strengthen HRSA's strategic thinking related to maternal health using input from maternal health experts, representatives of professional organizations, and the public at large.

Agenda: Topics that will be discussed include the following: Maternal health in the United States; current efforts to improve maternal health; gaps in the field; opportunities for collaborative efforts; and an overview of the National Maternal Health Initiative. Proposed